The Second Clinical College of Guangzhou University of Chinese Medicine

Chine

Retour au propriétaire

1-13 de 13 pour The Second Clinical College of Guangzhou University of Chinese Medicine Trier par
Recheche Texte
Affiner par
Juridiction
        International 12
        États-Unis 1
Date
2025 août 1
2025 (AACJ) 2
2024 3
2023 1
2022 5
Voir plus
Classe IPC
A61P 35/00 - Agents anticancéreux 4
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses 3
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS] 3
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés 2
A61K 31/365 - Lactones 2
Voir plus
Résultats pour  brevets

1.

LEIXIHAOKANG, PREPARATION METHOD THEREFOR, AND USE THEREOF

      
Numéro d'application CN2024081026
Numéro de publication 2025/166873
Statut Délivré - en vigueur
Date de dépôt 2024-03-11
Date de publication 2025-08-14
Propriétaire
  • GUANGDONG PROVINCIAL HOSPITAL OF TCM (Chine)
  • THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • THE SECOND CLINICAL COLLEGE OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • GUANGDONG PROVINCIAL ACADEMY OF CHINESE MEDICAL SCIENCES (Chine)
  • GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • GUANGZHOU INSTITUTE OF TRADITIONAL CHINESE MEDICINE (Chine)
Inventeur(s)
  • Liu, Bo
  • Wang, Xiaowan
  • Xu, Peng
  • Zheng, Bidan
  • Li, Ennian
  • Mao, Wei
  • Bao, Kun
  • Liang, Weihong
  • Li, Jianlong
  • Lu, Dongfang
  • Wu, Aihua
  • Wu, Yunshan
  • Xu, Fangfang
  • Chen, Weiying
  • Liang, Jinhao
  • Wang, Siyu
  • Chen, Xiuping
  • Zhong, Jinlang
  • Han, Xiaodong

Abrégé

The present invention belongs to the field of traditional Chinese medicines, and particularly relates to Leixihaokang, a preparation method therefor, and use thereof. The Leixihaokang of the present invention is prepared from the following active pharmaceutical ingredients in parts by weight: 10 parts of Tripterygium glycosides and 0.1-1.3 parts of Artemisia annua extract. According to the present invention, animal experiments prove that the Leixihaokang can ameliorate renal damage in nephrotic syndrome caused by adriamycin, reduce the occurrence of proteinuria, and reduce the apoptosis of renal tissue cells. Meanwhile, the Leixihaokang of the present invention has a good inhibitory effect on renal, hepatic, splenic, and cardiac toxicity in the treatment process of nephrotic syndrome. According to the present invention, animal experiments also prove that the Leixihaokang can ameliorate skin injury in imiquimod-induced psoriasis, reduce inflammatory infiltration and alleviate skin damage. Meanwhile, the Leixihaokang has a certain degree of inhibitory effect on the hepatic and reproductive system toxicity in the treatment process of psoriasis.

Classes IPC  ?

  • A61K 36/37 - Celastraceae (famille du bourreau des arbres ou de la camarine), p. ex. tripterygium ou fusain
  • A61K 36/282 - Artemisia, p. ex. armoise
  • A61K 31/585 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine contenant des cycles lactone, p. ex. oxandrolone, bufaline
  • A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
  • A61P 17/06 - Antipsoriasiques
  • A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe

2.

2-ARYL-2,3,4,5-TETRAHYDRO-1,4-EPOXYBENZAZEPINE COMPOUND AND USE THEREOF

      
Numéro d'application CN2024137774
Numéro de publication 2025/077945
Statut Délivré - en vigueur
Date de dépôt 2024-12-09
Date de publication 2025-04-17
Propriétaire
  • CHINESE MEDICINE GUANGDONG LABORATORY (Chine)
  • GUANGDONG PROVINCIAL HOSPITAL OF TCM (Chine)
  • THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • THE SECOND CLINICAL COLLEGE OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • GUANGDONG PROVINCIAL ACADEMY OF CHINESE MEDICAL SCIENCES (Chine)
Inventeur(s)
  • Liu, Bo
  • Li, Jianlong
  • Wang, Xuan
  • Du, Haifang
  • Wu, Yunshan
  • Liang, Weihong

Abrégé

A 2-aryl-2,3,4,5-tetrahydro-1,4-epoxybenzazepine compound having a structural formula as represented by formula I and the use thereof in the preparation of an anti-tumor drug. The 2-aryl-2,3,4,5-tetrahydro-1,4-epoxybenzazepine compound has good tumor cell proliferation inhibition activity against at least one among a human lung cancer cell A549, a human colon cancer cell HCT116, a human liver cancer cell HepG2, and a human breast cancer cell MCF-7.

Classes IPC  ?

  • C07D 498/08 - Systèmes pontés
  • A61K 31/537 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines condensées en spiro ou formant une partie de systèmes cycliques pontés
  • A61P 35/00 - Agents anticancéreux

3.

MEDICATED DIET COMPOSITION FOR TREATING HEAT COUGH, AND PREPARATION METHOD THEREFOR AND USE THEREOF

      
Numéro d'application CN2024082514
Numéro de publication 2024/153265
Statut Délivré - en vigueur
Date de dépôt 2024-03-19
Date de publication 2024-07-25
Propriétaire
  • GUANGDONG PROVINCIAL HOSPITAL OF TCM (Chine)
  • THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • THE SECOND CLINICAL COLLEGE OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • GUANGDONG PROVINCIAL ACADEMY OF CHINESE MEDICAL SCIENCES (Chine)
Inventeur(s)
  • Zhang, Zhongde
  • Guo, Jianwen
  • Tang, Lijuan
  • Liu, Yuntao
  • Jin, Lianshun

Abrégé

A medicated diet composition for treating a heat cough, prepared from the raw materials in the following parts by mass: 50-100 parts of kumquat, 30-50 parts of Eleocharis dulcis, 5-10 parts of Glehniae radix and 5-10 parts of Platycodonis radix. The medicated diet composition can improve the symptoms of a heat cough of a SARS-CoV-2 infection.

Classes IPC  ?

  • A61K 36/89 - Cyperaceae (famille de la laîche)
  • A61K 36/75 - Rutaceae (famille de la rue)
  • A61K 36/34 - Campanulaceae (famille de la campanule)
  • A61K 36/23 - Apiaceae ou Umbelliferae (famille de la carotte), p. ex. aneth, cerfeuil, coriandre ou cumin
  • A61P 11/14 - Antitussifs
  • A61P 31/14 - Antiviraux pour le traitement des virus ARN
  • A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

4.

MEDICATED DIET COMPOSITION FOR TREATING COLD COUGH, AND PREPARATION METHOD THEREFOR AND USE THEREOF

      
Numéro d'application CN2024082518
Numéro de publication 2024/153266
Statut Délivré - en vigueur
Date de dépôt 2024-03-19
Date de publication 2024-07-25
Propriétaire
  • GUANGDONG PROVINCIAL HOSPITAL OF TCM (Chine)
  • THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • THE SECOND CLINICAL COLLEGE OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • GUANGDONG PROVINCIAL ACADEMY OF CHINESE MEDICAL SCIENCES (Chine)
Inventeur(s)
  • Zhang, Zhongde
  • Guo, Jianwen
  • Tang, Lijuan
  • Liu, Yuntao
  • Jin, Lianshun

Abrégé

The present invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a medicated diet composition for treating a cold cough, and a preparation method therefor and the use thereof. The medicated diet composition of the present invention comprises the raw materials in the following parts by mass: 50-100 parts of kumquat, 10-20 parts of fresh ginger, 2-3 parts of Citri reticulatae pericarpium and 5-10 parts of Platycodonis radix. The medicated diet composition of the present invention can quickly improve the symptoms of a cold cough of a SARS-CoV-2 infection, and is particularly suitable for patients with a cold cough of a SARS-CoV-2 infection in regions where drug resources are relatively short, medical resources are relatively poor and the purchase of drugs is relatively difficult.

Classes IPC  ?

  • A61K 36/9068 - Zingiber, p. ex. gingembre
  • A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
  • A61P 11/14 - Antitussifs
  • A61P 31/14 - Antiviraux pour le traitement des virus ARN
  • A61P 11/04 - Médicaments pour le traitement des troubles du système respiratoire des maux de gorge
  • A61P 11/10 - Expectorants

5.

FORMULA FOR TONIFYING QI, ACTIVATING BLOOD AND DETOXIFICATING AND USE THEREOF

      
Numéro d'application CN2023135373
Numéro de publication 2024/114725
Statut Délivré - en vigueur
Date de dépôt 2023-11-30
Date de publication 2024-06-06
Propriétaire
  • GUANGDONG PROVINCIAL HOSPITAL OF TCM (Chine)
  • THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • THE SECOND CLINICAL COLLEGE OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • GUANGDONG PROVINCIAL ACADEMY OF CHINESE MEDICAL SCIENCES (Chine)
Inventeur(s)
  • Li, Jun
  • Tang, Guanghua
  • Ding, Banghan
  • Liu, Yuntao
  • Chen, Rui
  • Xu, Shengmei

Abrégé

Provided are a traditional Chinese medicine composition for tonifying Qi, activating blood and detoxificating and use thereof. The composition is prepared from the following ingredients: 10-30 parts of sun-dried ginseng, 6-30 parts of pseudo-ginseng, and 3-15 parts of Rheum officinale. The traditional Chinese medicine composition can ameliorate the illness state of patients suffering from sepsis secondary to pulmonary infection, and the oxygen saturation of the patients is improved by means of bowel-relaxing and anti-inflammation effects, thus shortening the mechanical ventilation time of the patients.

Classes IPC  ?

6.

Triptolide acrylate, preparation method therefor and use thereof

      
Numéro d'application 17790049
Numéro de brevet 11660285
Statut Délivré - en vigueur
Date de dépôt 2019-12-30
Date de la première publication 2023-03-02
Date d'octroi 2023-05-30
Propriétaire
  • Guangdong Provincial Hospital of TCM (Chine)
  • The Second Affiliated Hospital Of Guangzhou University of Chinese Medicine (Chine)
  • The Second Clinical College Of Guangzhou University of Chinese Medicine (Chine)
  • Guangdong Provincial Academy Of Chinese Medical Sciences (Chine)
Inventeur(s)
  • Liu, Bo
  • Huang, Xianzhang
  • Yang, Zhimin
  • Li, Jun
  • Chen, Quanfu
  • Han, Liqiao
  • Liang, Hualun
  • Yang, Yiqi
  • Wang, Kai
  • Wang, Xiaowan
  • Li, Ennian
  • Wang, Yi
  • Huang, Runyue
  • Wu, Yunshan
  • Han, Xiaodong
  • Zhong, Jinlang
  • Zheng, Bidan

Abrégé

Disclosed in the present invention is a new triptolide derivative as shown in formula (I). Also disclosed in the present invention are a preparation method for the compound and the medical use thereof in preparation of anti-cancer drugs. Triptolide acrylate of the present invention and a pharmaceutically acceptable salt thereof have anti-cancer activity, and after animal in-vivo experiments, can effectively inhibit tumor growth in animals. A plurality of in-vitro experiments proves that same can significantly increase the protein expression quantity of p53, promote the apoptosis of tumor cells, effectively inhibit the growth of the tumor cells, and have the effect of inhibiting metastasis of cancer cells. More importantly, the toxicity of the compound to normal cells is less than that of triptolide.

Classes IPC  ?

  • A61K 31/365 - Lactones
  • A61P 35/00 - Agents anticancéreux
  • C07J 73/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène modifié par substitution d'un ou deux atomes de carbone par des hétéro-atomes

7.

TRADITIONAL CHINESE MEDICINE FOR TREATMENT OF DIABETIC NEPHROPATHY

      
Numéro d'application CN2021141274
Numéro de publication 2022/242173
Statut Délivré - en vigueur
Date de dépôt 2021-12-24
Date de publication 2022-11-24
Propriétaire
  • GUANGDONG PROVINCIAL HOSPITAL OF TCM (Chine)
  • THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • THE SECOND CLINICAL COLLEGE OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • GUANGDONG PROVINCIAL ACADEMY OF CHINESE MEDICAL SCIENCES (Chine)
Inventeur(s)
  • Liu, Xusheng
  • Zhang, Lei
  • Lu, Fuhua
  • Chen, Guowei
  • Xu, Yuan
  • Zhang, La
  • Su, Jingxu
  • Hu, Xiaoxuan
  • Zheng, Tingting
  • Wu, Yifan
  • Jie, Xina
  • Liu, Hui
  • Xie, Xiaoning
  • Fu, Lizhe

Abrégé

A traditional Chinese medicine for the treatment of diabetic nephropathy, comprising the following raw materials in parts by weight: 9-30 parts of radix astragali, 6-15 parts of semen cuscutae, 5-10 parts of peach kernel, 3-10 parts of rhizoma atractylodis, 3-10 parts of dried tangerine peel, 15-30 parts of centella asiatica, and 3-10 parts of cordyceps cicadae.

Classes IPC  ?

  • A61K 36/752 - Citrus, p. ex. citron vert, orange ou citron
  • A61K 35/64 - Insectes, p. ex. abeilles, guêpes ou puces
  • A61P 37/02 - Immunomodulateurs
  • A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
  • A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques

8.

COMPOSITION FOR PREVENTING RHEUMATOID ARTHRITIS, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

      
Numéro d'application CN2021111561
Numéro de publication 2022/227331
Statut Délivré - en vigueur
Date de dépôt 2021-08-09
Date de publication 2022-11-03
Propriétaire
  • GUANGDONG PROVINCIAL HOSPITAL OF TCM (Chine)
  • THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • THE SECOND CLINICAL COLLEGE OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • GUANGDONG PROVINCIAL ACADEMY OF CHINESE MEDICAL SCIENCES (Chine)
Inventeur(s)
  • Huang, Runyue
  • Wen, Zehuai
  • Huang, Qingchun
  • Zhao, Yue
  • Wu, Xiaodong
  • Chen, Xiumin
  • Xia, Xuan
  • Guo, Xiaohui

Abrégé

The present invention belongs to the field of traditional Chinese medicine, and in particular, to a composition for preventing rheumatoid arthritis, a preparation method therefor, and an application thereof. The composition for preventing rheumatoid arthritis of the present invention is prepared from the following raw material components in parts by mass: 15-60 parts of raw Semen Coicis, 5-30 parts of Radix Angelicae Sinensis, 5-30 parts of Radix Paeoniae Alba, 1-15 parts of Herba Ephedrae, 5-30 parts of Ramulus Cinnamomi, 5-30 parts of Radix Glycyrrhizae Praeparata, 5-30 parts of Rhizoma Atractylodis, and 10-60 parts of Radix Astragali. Proved by a CIA rat model experiment, the composition for preventing rheumatoid arthritis of the present invention can obviously alleviate the joint swelling degree of a CIA rat, X ray shows that bone destruction can be improved, and a pathological section shows good effects of inhibiting synovial tissue proliferation, reducing inflammatory cell infiltration, and delaying bone and cartilage destruction, thereby achieving the effects of symptom improvement, bone protection and anti-inflammatory for the CIA rat.

Classes IPC  ?

  • A61K 36/8994 - Coix (Lacrimia Jobi)
  • A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
  • A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

9.

COMPOSITION FOR PREVENTING AND/OR TREATING RHEUMATOID ARTHRITIS, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

      
Numéro d'application CN2021111562
Numéro de publication 2022/227332
Statut Délivré - en vigueur
Date de dépôt 2021-08-09
Date de publication 2022-11-03
Propriétaire
  • GUANGDONG PROVINCIAL HOSPITAL OF TCM (Chine)
  • THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • THE SECOND CLINICAL COLLEGE OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • GUANGDONG PROVINCIAL ACADEMY OF CHINESE MEDICAL SCIENCES (Chine)
Inventeur(s)
  • Huang, Runyue
  • Wen, Zehuai
  • Huang, Qingchun
  • Zhao, Yue
  • Wu, Xiaodong
  • Chen, Xiumin
  • Xia, Xuan
  • Guo, Xiaohui

Abrégé

A composition for preventing and/or treating rheumatoid arthritis, a preparation method therefor, and an application thereof. The composition is made from the following raw material components in parts by mass: 10-40 parts of Radix Salviae Miltiorrhizae, 15-120 parts of Rhizoma Dioscoreae Nipponicae, 15-60 parts of Radix Astragali, 5-30 parts of Radix Paeoniae Alba, 3-15 parts of Ephedra, 3-15 parts of Radix Aconiti Laterailis Prepareata, 5-30 parts of Morinda Officinalis, and 5-30 parts of honey-fried licorice root. By means of clinical tests, it is proven that said composition can alleviate the symptoms of articulation swelling and suffered by patients, control the level of inflammation and disease progression, and has potential bone protection effects.

Classes IPC  ?

  • A61K 36/8945 - Dioscorea, p. ex. igname, Dioscorea opposita ou Dioscorea alata
  • A61K 36/746 - Morinda
  • A61K 36/714 - Aconitum (aconit)
  • A61K 36/71 - Ranunculaceae (famille du bouton d'or), p. ex. pied d'alouette, hépatique, hydrastis, ancolie
  • A61K 36/65 - Paeoniaceae (famille de la pivoine), p. ex. pivoine chinoise
  • A61K 36/537 - Salvia (sauge)
  • A61K 36/484 - Glycyrrhiza (réglisse)
  • A61K 36/481 - Astragalus (astragalus cicer)
  • A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
  • A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
  • A61P 19/08 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget

10.

COMPOSITION FOR PREVENTING AND/OR TREATING RHEUMATOID ARTHRITIS, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

      
Numéro d'application CN2021111563
Numéro de publication 2022/227333
Statut Délivré - en vigueur
Date de dépôt 2021-08-09
Date de publication 2022-11-03
Propriétaire
  • GUANGDONG PROVINCIAL HOSPITAL OF TCM (Chine)
  • THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • THE SECOND CLINICAL COLLEGE OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • GUANGDONG PROVINCIAL ACADEMY OF CHINESE MEDICAL SCIENCES (Chine)
Inventeur(s)
  • Huang, Runyue
  • Wen, Zehuai
  • Huang, Qingchun
  • Zhao, Yue
  • Wu, Xiaodong
  • Chen, Xiumin
  • Xia, Xuan
  • Guo, Xiaohui

Abrégé

The present invention belongs to the field of traditional Chinese medicines, and in particular relates to a composition for preventing and/or treating rheumatoid arthritis, a preparation method therefor and an application thereof. The composition for preventing and/or treating rheumatoid arthritis of the present invention is prepared from the following raw material components in parts by mass: 5-30 parts Notopterygium root, 5-45 parts kadsura pepper stem, 3-20 parts of prepared aconite root, 5-30 parts of Gentiana macrophylla, 5-30 parts of ramulus mori, 5-30 parts of Angelica sinensis, 5-20 parts of Ligusticum wallichii, 3-15 parts of Costustoot, and 3-30 parts of Radix glycyrrhizae preparata. According to clinical trials, the composition for preventing and/or treating rheumatoid arthritis of the present invention can improve the symptoms of joint swelling and pain in patients, control inflammation levels and disease progression, and has potential bone protection effects.

Classes IPC  ?

  • A61K 36/714 - Aconitum (aconit)
  • A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
  • A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

11.

APPLICATION OF GLUTAMINASE INHIBITOR IN PREPARATION OF DRUG FOR TREATING PSORIASIS

      
Numéro d'application CN2021101850
Numéro de publication 2022/001784
Statut Délivré - en vigueur
Date de dépôt 2021-06-23
Date de publication 2022-01-06
Propriétaire
  • GUANGDONG PROVINCIAL HOSPITAL OF TCM (Chine)
  • THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • THE SECOND CLINICAL COLLEGE OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • GUANGDONG PROVINCIAL ACADEMY OF CHINESE MEDICAL SCIENCES (Chine)
Inventeur(s)
  • Lu, Chuanjian
  • Xu, Yongyue
  • Wang, Maojie
  • Huang, Runyue
  • Boudewijn, Burgering
  • Jiao, Lin

Abrégé

Disclosed in the present invention is an application of a glutaminase inhibitor in preparation of a drug for treating psoriasis. According to the present invention, in-vitro cell experiments prove that the glutaminase inhibitor can inhibit keratinocyte metabolism glutamine, inhibit miR-31 induced up-regulated keratinocyte mitochondrial respiration, inhibit miR-31 induced mTOR pathway, reduce cell activity and promote cell apoptosis, and has an anti-inflammatory effect; animal experiments prove that the glutaminase inhibitor can be used for effectively treating imiquimod-induced mouse psoriasis-like pathology change, comprising remarkably reducing a Baker score of a skin lesion, effectively reducing an epidermal hypertrophy degree, remarkably reducing the number of subepidermal capillaries, remarkably reducing the number of epidermal Ki67 positive cells and reducing the expression of epidermal GLS. Therefore, the glutaminase inhibitor can be used for preparing a drug for treating psoriasis.

Classes IPC  ?

  • A61K 31/42 - Oxazoles
  • A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
  • A61K 31/473 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. acridines, phénantridines
  • A61K 31/433 - Thiadiazoles
  • A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
  • A61P 17/06 - Antipsoriasiques

12.

TRIPTOLIDE ACRYLATE, PREPARATION METHOD THEREFOR AND USE THEREOF

      
Numéro d'application CN2019130056
Numéro de publication 2021/134272
Statut Délivré - en vigueur
Date de dépôt 2019-12-30
Date de publication 2021-07-08
Propriétaire
  • GUANGDONG PROVINCIAL HOSPITAL OF TCM (Chine)
  • THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • THE SECOND CLINICAL COLLEGE OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • GUANGDONG PROVINCIAL ACADEMY OF CHINESE MEDICAL SCIENCES (Chine)
Inventeur(s)
  • Liu, Bo
  • Huang, Xianzhang
  • Han, Liqiao
  • Yang, Yiqi
  • Wang, Kai
  • Wu, Yunshan
  • Wang, Xiaowan
  • Li, Ennian
  • Wang, Yi
  • Huang, Runyue
  • Han, Xiaodong
  • Zhong, Jinlang
  • Lu, Jinjian
  • Zhang, Yuqin
  • Zhu, Chunxiang

Abrégé

Disclosed in the present invention is a new triptolide derivative as shown in formula (I). Also disclosed in the present invention are a preparation method for the compound and the medical use thereof in the preparation of anti-cancer drugs. The triptolide acrylate of the present invention and pharmaceutically acceptable salts thereof have anti-cancer activity, and after animal in-vivo experiments, can effectively inhibit tumor growth in animals. A plurality of in-vitro experiments prove that same can significantly increase the protein expression quantity of p53, promote the apoptosis of tumor cells, effectively inhibit the growth of the tumor cells, and have the effect of inhibiting cancer cell metastasis. More importantly, the toxicity of the compound to normal cells is less than that of triptolide.

Classes IPC  ?

  • C07D 493/22 - Composés hétérocycliques contenant des atomes d'oxygène comme uniques hétéro-atomes dans le système condensé dans lesquels le système condensé contient au moins quatre hétérocycles
  • C07J 73/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène modifié par substitution d'un ou deux atomes de carbone par des hétéro-atomes
  • A61K 31/365 - Lactones
  • A61P 35/00 - Agents anticancéreux

13.

APPLICATIONS OF PSORALEN IN PREPARING NRF2 INHIBITOR, MEDICAMENT FOR NRF2 INHIBITION-RELATED DISEASES, AND ANTICANCER MEDICAMENT

      
Numéro d'application CN2019092968
Numéro de publication 2020/215481
Statut Délivré - en vigueur
Date de dépôt 2019-06-26
Date de publication 2020-10-29
Propriétaire
  • GUANGDONG PROVINCIAL HOSPITAL OF TCM (Chine)
  • THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • THE SECOND CLINICAL COLLEGE OF GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (Chine)
  • GUANGDONG PROVINCIAL ACADEMY OF CHINESE MEDICAL SCIENCES (Chine)
Inventeur(s)
  • Zhang, Zhongde
  • Wang, Yuanyuan
  • Wang, Dawei
  • Chen, Weimin

Abrégé

Applications of psoralen in preparing an Nrf2 inhibitor, a medicament for Nrf2 inhibition-related diseases, and an anticancer medicament. Psoralen reduces the level of Nrf2 protein expression, reduces the antioxidative stress ability of human non-small cell lung carcinoma A549 cells, and increases the proapoptotic effects of chemotherapeutic medicament cisplatin with respect to A549. Psoralen has no significant impact on animal liver and kidneys when used as a medicament.

Classes IPC  ?

  • A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
  • A61K 33/243 - PlatineSes composés
  • A61P 35/00 - Agents anticancéreux